Your AI-Trained Oncology Knowledge Connection!
December 23, 2020 — Although SGX942 was found to induce clinically meaningful reductions in severe oral mucositis vs placebo in patients with head and neck cancer, the benefit failed to reach statistical significance, thus missing the primary end point of the phase 3 DOM-INNATE study.
December 23, 2020 - Entrectinib continued to demonstrate clinically meaningful, durable responses with a manageable toxicity profile in patients with NTRK fusion–positive sarcoma.
December 23, 2020 - The FDA has updated the prescribing information for ibrutinib to include safety and efficacy data for the agent in combination with rituximab in the treatment of patients with Waldenström macroglobulinemia.
December 22, 2020 - Patients with polycythemia vera who received ropeginterferon alfa-2b had a higher likelihood of being phlebotomy free in the fourth or fifth year of treatment vs those who received best available therapy.
December 22, 2020 — Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor–positive, estrogen receptor–positive metastatic breast cancer.
December 22, 2020 - Idasanutlin, an investigational MDM2 antagonist that leads to increased p53 activity, led to hematologic responses in about two-thirds of patients with hydroxyurea-resistant polycythemia vera, but was associated with frequent discontinuation.
December 22, 2020 — Intravesical Bacillus Calmette-Guerin in combination with N-803 was found to induce a complete response rate of 72% in patients with non-muscle invasive bladder cancer in high-risk carcinoma in situ disease, meeting the primary end point of the phase 2/3 QUILT 3.032 trial.
December 22, 2020 - Minimum residual disease negativity in the bone marrow and peripheral blood prior to autologous stem cell transplant predicts better progression-free survival and overall survival in younger patients with mantle cell lymphoma.
The small interfering RNA therapeutic STP705 has been found to induce high rates of histological clearance with a favorable toxicity profile in patients with squamous cell skin cancer.
December 22, 2020 — The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.
December 21, 2020 — The addition of gilteritinib to azacitidine failed to significantly improve overall survival vs azacitidine alone in patients with newly diagnosed FLT3-mutated acute myeloid leukemia who were not eligible for intensive induction chemotherapy, failing to meet the primary end point of the LACEWING trial.
December 21, 2020 - Cabozantinib was found to significantly improve progression-free survival compared with placebo in patients with dedifferentiated thyroid cancer who are refractory to radioiodine and have progressed following up to 2 prior VEGF-targeted treatments.
December 21, 2020 - The submission of a biologics license application to the FDA has been initiated for JZP-458 for use as a component of a multiagent chemotherapy regimen in the treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.
December 21, 2020 — The 5-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide showed a tolerable safety profile and encouraging antitumor activity with complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
December 21, 2020 - Interferon-alpha can delay and possibly prevent post-PV myelofibrosis and improve survival in patients with polycythemia vera.
December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.
December 21, 2020 - The National Comprehensive Cancer Network has added 3 selinexor combination regimens to its Clinical Practice Guidelines in Oncology for previously treated patients with multiple myeloma.
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.
Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.
December 18, 2020 - The FDA has granted Emergency Use Authorization to the second vaccine to prevent coronavirus disease 2019 infection.
December 18, 2020 - The FDA has approved ponatinib for the treatment of patients with chronic-phase chronic myeloid leukemia that is resistant or intolerant to at least 2 prior kinase inhibitors.
December 18, 2020 - The FDA has approved osimertinib for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
December 18, 2020 - The FDA has approved the oral gonadotropin-releasing hormone receptor antagonist relugolix as a treatment for patients with advanced prostate cancer.
December 18, 2020 - Sequential immunotherapy with rituximab-based therapy and the addition of lenalidomide proved effective among patients with TP53 wild-type mantle cell lymphoma, even among those with a Ki-67 level of at least 30% and/or blastoid morphology.
December 18, 2020 - The FDA has approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 previous therapy.
December 18, 2020 - A supplemental new drug application has been submitted to the FDA for avapritinib for use as a treatment in adult patients with advanced systemic mastocytosis.
Javier L. Munoz, MD, discusses the nuances of choosing treatment options for patients with CLL in the frontline and relapsed/refractory settings, as well as novel therapeutic strategies on the horizon.
Although basal cell carcinoma generally has a good prognosis, improving tolerance to targeted Hedgehog inhibitors and optimizing second-line treatment with immune checkpoint inhibitors are important for the small subset of patients who develop locally advanced or metastatic disease.
December 17, 2020 - The FDA’s Vaccines and Related Biological Products Advisory Committee has voted 20-0 with 1 abstention to support the benefit-risk profile associated with the coronavirus disease 2019 vaccine mRNA-1273.
